ИСТИНА

Platinum complexes dominate the field of metal-based cancer chemotherapy. The success of these compounds incited the search for the new metal-based anticancer drugs. After platinum drugs, ruthenium compounds became the most promising metal-based antitumor agents with similar to cell cycle binding kinetics, different molecular targets and possibility for the active intracellular transport. One of the approaches for design of new metal-based drugs is incorporating the biological active molecules into known anticancer metal complex.